Tweet
Have they gone the way of Helicos?
-
-
Too early to say. They could be just re-positioning the emphasis of their workforce. But paring down the work force of a supposedly growing company is rarely a good sign. Glad I didn't apply for any of those numerous PacBio posts in the "Industry Jobs" section. :-) -
Many are supposed to be in the "R&D" section, which is probably not good news either.Comment
-
They did go on a gangbuster hiring spree prior to their IPO, and are probably discovering that the revenue cannot support the workforce expansion. With their main strength relative to the competition being long segment reads, it is a valid question to ask whether there is a sustainable commercial position there. After all, how much denovo sequencing is needed on a large scale? On the surface GNOM would appear to be targeting a more sustainable commercial target. Thoughts?Comment
-
The sequencing world is rapidly changing due to declining costs, enhanced accuracies, and the advent of newer, cutting-edge instruments. Equally important to these developments are improvements in sequencing analysis, a process that converts vast amounts of raw data into a comprehensible and meaningful form. This complex task requires expertise and the right analysis tools. In this article, we highlight the progress and innovation in sequencing analysis by reviewing several of the...05-06-2024, 07:48 AM -
The field of epigenetics has traditionally concentrated more on DNA and how changes like methylation and phosphorylation of histones impact gene expression and regulation. However, our increased understanding of RNA modifications and their importance in cellular processes has led to a rise in epitranscriptomics research. “Epitranscriptomics brings together the concepts of epigenetics and gene expression,” explained Adrien Leger, PhD, Principal Research Scientist...04-22-2024, 07:01 AM
Comment